Lugano, Switzerland, April 21, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first […]

Lugano, Switzerland, April 13, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce […]

BridgeBio, through its Affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. […]

Lugano, Switzerland, March 23, 2021 – Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, “Helsinn”) is pleased to announce that its Japanese partner Taiho Pharmaceutical Co., […]

Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note […]

Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note […]

Lugano, Switzerland, and Osaka, Japan, January 22, 2021 – Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, “Helsinn”) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President […]

Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first […]

Columbia University has launched a new fellowship funded with a grant from Helsinn. The fellowship program will focus on mycosis fungoides, a type of cutaneous […]

Lugano, Switzerland, December 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to be […]